Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 908 matching trials from the live ClinicalTrials.gov search.
Conditions
Macular Degeneration
Interventions
MSI-1256F (Squalamine Lactate)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
9
States / cities
Boynton Beach, Florida • Fort Meyers, Florida • Miami, Florida + 6 more
Conditions
Macular Edema, Epiretinal Membrane, Vitrectomy
Interventions
Dexamethasone
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Age Related Macular Degeneration, Geographic Atrophy
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Oakland, California • Jackson, Michigan
Terminated No phase listed Observational Accepts healthy volunteers

PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration

NCT02779686
Conditions
Age-Related Macular Degeneration (ARMD)
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
60 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Chicago, Illinois • Chesterfield, Missouri • Columbia, Missouri
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
FWY003, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Huntington Beach, California • Sacramento, California • Santa Barbara, California + 11 more
Conditions
Geographic Atrophy
Interventions
RNA-144101
Drug
Lead sponsor
Mark Kleinman
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Macular Edema
Interventions
dexamethasone 700 ㎍ intravitreal implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Santa Ana, California + 15 more
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Prism Vision Group
Other
Eligibility
65 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Edison, New Jersey
Conditions
Neovascular Age-related Macular Degeneration
Interventions
CLS-AX
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 4 more
Conditions
Age Related Macular Degeneration
Interventions
Ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Macular Degeneration
Interventions
Anecortave Acetate Sterile Suspension (15 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
50 Years and older
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

NCT06924021
Conditions
Age-Related Macular Degeneration
Interventions
Retinal Imaging
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Fargo, North Dakota • Erie, Pennsylvania • Dallas, Texas + 4 more
Completed No phase listed Observational Accepts healthy volunteers

Study Evaluating Retinal Health Monitoring System Visual Acuity Module.

NCT04169802
Conditions
Age Related Macular Degeneration
Interventions
Retinal Health Monitoring System Visual Acuity Module, Sloan letter, logarithmic near visual acuity chart (Reference Chart)
Diagnostic Test
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
ADX-038, Placebo
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
21
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 18 more
Not listed Not applicable Interventional

Telescope Exchange Study

NCT03011554
Conditions
Age-related Macular Degeneration
Interventions
Implantable Miniature Telescope (IMT)
Device
Lead sponsor
VisionCare, Inc.
Industry
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 11 more
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
PDS Implant with Ranibizumab 100 mg/mL
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
81
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more
Conditions
Geographic Atrophy
Interventions
BRX011, Placebo
Drug
Lead sponsor
Biojiva LLC
Industry
Eligibility
55 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Gilbert, Arizona • Phoenix, Arizona • Hattiesburg, Mississippi + 8 more
Conditions
Neovascular (Wet) Age-related Macular Degeneration (AMD)
Interventions
ABP 938, Aflibercept
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Fullerton, California • La Jolla, California + 36 more
Conditions
Macular Degeneration
Interventions
TAC-PF, Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
Conditions
Age-Related Macular Degeneration
Interventions
Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
Drug · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions
Faricimab, Port Delivery System with Ranibizumab
Drug · Combination Product
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more
Conditions
Non-infectious Intermediate and Posterior Uveitis
Interventions
Methotrexate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Brain Connectivity in Age-Related Macular Degeneration

NCT01996215
Conditions
Age-Related Macular Degeneration
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
50 Years to 90 Years
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, dexamethasone and verteporfin, Ranibizumab
Drug
Lead sponsor
Bay Area Retina Associates
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Castro Valley, California • Walnut Creek, California • Riverdale, Georgia + 1 more